Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Taproot Health
Fore Biotherapeutics
Celgene
Stanford University